Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia

Main Article Content

Alhossain A. Khalafallah
Bernadene Fernandopulle
Terry Brain

Keywords

Intermediate, high-risk MDS, IPSS, lenalidomide, hematological response, dose-modified.

Abstract

No Abstract Available

Downloads

Download data is not yet available.
Abstract 693 | PDF Downloads 376 HTML Downloads 267

Most read articles by the same author(s)